Evgeny Zaytsev - 02 Jul 2026 Form 3 Insider Report for CalciMedica, Inc. (CALC)

Reporting relationship: Director
Issuer ticker: CALC
Reported as of: 02 Jul 2026
Net transaction value: $0
SEC form: 3
Accepted by SEC: 07 Jul 2026, 16:59:33 UTC
Next SEC filing: 21 Aug 2026
Source filing: View source filing
Reporting owner signature: /s/ John Dunn, Esq., Attorney-in-Fact

Key filing fact

Evgeny Zaytsev filed Form 3 for CalciMedica, Inc. (CALC) on 07 Jul 2026.

Key facts

This page summarizes Evgeny Zaytsev's Form 3 filing for CalciMedica, Inc. (CALC).
0 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 07 Jul 2026, 16:59.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0001674797 Primary reporting owner

Zaytsev Evgeny

Relationship: Director
Address: C/O CALCIMEDICA, INC., 505 COAST S. BLVD, SUITE 300-9, LA JOLLA
Signature: /s/ John Dunn, Esq., Attorney-in-Fact
Signature date: 07 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CALC holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 2,113,513
Date: 02 Jul 2026
Ownership: By Bering Partners II, L.P.
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CALC holding Derivative

Warrant

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 02 Jul 2026
Ownership: By Bering Partners II, L.P.
Underlying class: Common Stock
Underlying amount: 130,651
Exercise price: $7.15
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The securities are held by Bering Partners II, L.P. ("Bering II"). Bering Partners II GP, L.L.C. ("Bering II GP") is the general partner of Bering II and may be deemed to have voting and dispositive power over the securities held by Bering II. The Reporting Person, a member of the Issuer's board of directors, and Philip Sawyer are the managing members of Bering II GP and may be deemed to have voting and dispositive power with respect to these securities. Each of Bering II GP, the Reporting Person and Mr. Sawyer disclaim beneficial ownership of the securities held by Bering II, except to the extent of such person's pecuniary interest therein.

Footnote F2

The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (ET) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter; provided, however, that the holder will be prohibited, subject to certain exceptions, from exercising such warrant for shares of common stock of the Issuer to the extent that immediately prior to or after giving effect to such exercise, the holder, together with its affiliates and other attribution parties, would own more than 4.99% of the total number of shares of common stock of the Issuer then issued and outstanding, which percentage may be changed at the holder's election to a lower percentage at any time or to a higher percentage upon 61 days' notice to the Issuer. On July 2, 2026, Bering II provided notice to the Issuer to increase such percentage to 19.99%.